Effect of surotomycin, a novel cyclic lipopeptide antibiotic, on intestinal colonization with vancomycin-resistant enterococci and klebsiella pneumoniae in mice

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 6, 2016, Pages 3333-3339

  Deshpande, Abhishek ^a,b   Hurless, Kelly ^b   Cadnum, Jennifer L ^b   Chesnel, Laurent ^c   Gao, Lihong ^c   Chan, Luisa ^d   Kundrapu, Sirisha ^b   Polinkovsky, Alexander ^b   Donskeyb, Curtis J ^a,b,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Bioinformatics Department   (United States)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; SODIUM CHLORIDE; SUROTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BACTEROIDETES; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FECES ANALYSIS; FEMALE; FIRMICUTES; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE INFECTION; LIMIT OF DETECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOBACTERIA; SINGLE DRUG DOSE; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; GRAM-NEGATIVE BACTERIA; KLEBSIELLA PNEUMONIAE; LIPOPEPTIDES; METRONIDAZOLE; MICE; PEPTIDES, CYCLIC; VANCOMYCIN; VANCOMYCIN RESISTANCE; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84973623387     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02904-15     Document Type: Article

References (24)

1. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi .org/10.1056/NEJMoa0910812.
2. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55(Suppl 2):S132-S142. http://dx.doi.org/10.1093/cid/cis338.
3. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficileinfected patients than does vancomycin. Microbiology 156:3354 -3359. http://dx.doi.org/10.1099/mic.0.042010-0.
4. Al-Nassir W, Sethi AK, Riggs MM, Li Y, Pultz MJ, Donskey CJ. 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52:2403-2406. http://dx.doi.org/10.1128/AAC.00090-08.
5. Sethi AK, Al-Nassir W, Nerandzic MM, Donskey CJ. 2009. Skin and environmental contamination with vancomycin-resistant enterococci in patients being treated with oral metronidazole versus oral vancomycin for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 30: 13-17. http://dx.doi.org/10.1086/592710.
6. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with fidaxomicin versus vancomycin for C. difficile infection. Clin Infect Dis 55(Suppl 2):S121-S126. http://dx.doi .org/10.1093/cid/cis440.
7. Citron DM, Goldstein EJ. 2011. Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile. Diagn Microbiol Infect Dis 70:554 -556. http://dx.doi.org/10.1016/j.diagmicrobio.2011.04.012.
8. Snydman DR, Jacobus NV, McDermott LA. 2012. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 56:3448 -3452. http://dx.doi.org/10.1128/AAC .06257-11.
9. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 56:1613-1615. http://dx.doi.org/10.1128/AAC.05655-11.
10. Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA. 2012. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 56:5023-5030. http://dx.doi.org/10.1128/AAC.00057-12.
11. Cannon K, Byrne B, Happe J, Louie T. 2012. Abstr 22nd Eur Cong Clin Microbiol Infect Dis, abstr P-2250. Enteric microbiome profiles during a phase 2 clinical trial of CB-183, 315 or vancomycin for treatment of Clostridium difficile infection.
12. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. 2000. Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 181:1830 -1833. http://dx.doi.org/10.1086/315428.
13. Hoyen CK, Pultz NJ, Paterson DL, Aron DC, Donskey CJ. 2003. Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extendedspectrum ô-lactamases. Antimicrob Agents Chemother 47:3610 -3612. http://dx.doi.org/10.1128/AAC.47.11.3610-3612.2003.
14. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Clinical and Laboratory Standards Institute. 2005. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Traczewski MM, Deane J, Sahm D, Brown SD, Chesnel L. 16 December 2015. Impact of variations in test method parameters on in vitro activity of surotomycin against Clostridium difficile and surotomycin quality control limits for broth microdilution and agar dilution susceptibility testing. J Clin Microbiol http://dx.doi.org/10.1128/JCM.02881-15.
17. Rolfe RD, Finegold SM. 1983. Intestinal ô-lactamase activity in ampicillin-induced, Clostridium difficile-associated ileocecitis. J Infect Dis 147: 227-235. http://dx.doi.org/10.1093/infdis/147.2.227.
18. Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier LC, Valiquette L. 2010. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 10:363. http://dx.doi.org/10.1186/1471-2334-10-363.
19. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. 1999. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 180: 384 -390. http://dx.doi.org/10.1086/314874.
20. Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC, Gobourne A, Ling L, Pamer EG. 2015. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis 212:1656 -1665. http: //dx.doi.org/10.1093/infdis/jiv256.
21. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. 1992. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 117:297-302.
22. Bolton RP, Culshaw MA. 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27:1169 -1172. http://dx.doi.org/10.1136/gut.27 .10.1169.
23. Jump RL, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, Deshpande A, Nerandzic MM, Donskey CJ. 2014. Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. PLoS One 9:e101267. http://dx .doi.org/10.1371/journal.pone.0101267.
24. Vincent C, Stephens DA, Loo VG, Edens TJ, Behr MA, Dewar K, Manges AR. 2013. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome 1:18. http://dx.doi.org/10.1186/2049-2618-1-18.